Andrology Center, Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, No. 59A, Di'anmen West St., Xicheng District, Beijing, 100034, China.
Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
BMC Urol. 2020 Feb 3;20(1):11. doi: 10.1186/s12894-020-0580-3.
The treatment effect of dapoxetine in real-world practice is not well established. This study was to investigate the factors influencing efficacy of dapoxetine for the treatment of Premature ejaculation (PE) in the real-world setting.
Altogether 154 patients were followed up between Jan 2015 and Dec 2015. The clinical global impression of change (CGIC), premature ejaculation profile (PEP), the estimated intravaginal ejaculation latency time (eIELT) and estimated number of intravaginal thrusts before ejaculation (NITBE) were collected. The clinical characteristics of patients with CGIC = 0 and CGIC≥1 were compared.
After 4 weeks treatment, an obvious improvement compared with the baseline was found regarding mean eIELT (2.4 ± 1.6 min vs 1.0 ± 0.7 min, P < 0.001) and mean NITBE (85.9 ± 61.9 times vs 37.4 ± 28.6 times, P < 0.001). The proportion of patients with a self-evaluation of at least "slightly better" and were categorized into "CGIC≥1" group was 70.1%. There were significant differences between patients in the "CGIC = 0" and "CGIC≥1" groups regarding mean NITBE (P = 0.010) and PEDT (P = 0.009) score at baseline. The adverse effects were acceptable.
Dapoxetine was well-tolerated and improved the sexual satisfaction of patients with PE. The severity of PE based on PEDT and NITBE suggest that there could be an effectiveness change with dapoxetine use in real-world practice.
达泊西汀在真实世界实践中的治疗效果尚未得到充分证实。本研究旨在探讨影响达泊西汀治疗早泄（PE）疗效的因素。
共 154 例患者于 2015 年 1 月至 2015 年 12 月进行随访。收集临床总体印象变化量表（CGIC）、早泄评估问卷（PEP）、估计阴道内射精潜伏期时间（eIELT）和估计射精前阴道内抽动次数（NITBE）。比较 CGIC=0 和 CGIC≥1 的患者的临床特征。
治疗 4 周后，与基线相比，平均 eIELT（2.4±1.6 分钟比 1.0±0.7 分钟，P<0.001）和平均 NITBE（85.9±61.9 次比 37.4±28.6 次，P<0.001）均明显改善。自我评估至少“略有改善”的患者比例为 70.1%，归入“CGIC≥1”组。在平均 NITBE（P=0.010）和 PEDT 评分（P=0.009）方面，“CGIC=0”和“CGIC≥1”两组患者存在显著差异。不良反应可接受。
达泊西汀耐受性良好，可提高 PE 患者的性满意度。基于 PEDT 和 NITBE 的 PE 严重程度表明，达泊西汀在真实世界实践中可能会产生疗效变化。
